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Background: In coronary bifurcation lesions, little is known about the effect of re-
sidual side branch (SB) stenosis after main vessel (MV) stenting on long-term clinical
outcomes.
Methods: A total of 2,897 consecutive patients who underwent percutaneous coro-
nary intervention using a drug-eluting stent for a coronary bifurcation lesion with a SB
 2.3 mm were enrolled from 18 centers in South Korea. Of these, we analyzed data
from 1,563 patients who were treated with 1-stent technique for non-Left main
bifurcation lesions and ﬁnally have TIMI ﬂow grade 3 of the SB. We compared
cardiac death or myocardial infarction according to residual diameter stenosis (DS) of
the SB ostium in those patients.
Results: 574 patients have residual SB DS 50%, and 989 patients residual SB DS <
50% after the index procedure. During a median follow-up duration of 37 months,
patients with residual SB DS 50% have a higher incidence of cardiac death or
myocardial infarction (1.4 versus 3.3%, p¼0.01) than those with residual SB DS <
50%. Multivariate analysis revealed a higher risk of cardiac death or myocardial
infarction (hazard ratio [HR], 2.52; 95% conﬁdence interval [CI], 1.20-5.28; P¼0.02)
in the residual SB DS 50% group compared to the residual SB DS < 50% group.Table. Clinical Outcomes.
n¼1,563
rSB DS
<50%
rSB DS
50% Unadjusted HR p
Value
Adjusted HR p
Value
(n¼989) (n¼574) (95% CI) (95% CI)
All cause death 26 (2.6) 20 (3.5) 1.48 (0.83-2.66) 0.19 1.14 (0.61-2.12) 0.68
Cardiac death 6 (0.6) 7 (1.2) 2.14 (0.72-6.37) 0.17 1.82 (0.56-5.91) 0.32
MI 9 (0.9) 12 (2.1) 2.66 (1.12-6.31) 0.03 2.90 (1.15-7.32) 0.03
Cardiac death or
MI
14 (1.4) 19 (3.3) 2.63 (1.32-5.26) 0.01 2.52 (1.20-5.28) 0.02
Stent thrombosisy 3 (0.3) 3 (0.5) 1.87 (0.38-9.30) 0.44 1.44 (0.27-7.69) 0.67
TLR 62 (6.3) 39 (6.8) 1.22 (0.82-1.83) 0.33 1.26 (0.82-1.94) 0.29
*Adjusted covariates included history of chronic renal failure, bifurcation location, true
bifurcation, and SB DS before procedure.
yDeﬁnite or probable stent thrombosis.
TLF ¼ cardiac death, MI, or TLR
CDMI ¼ cardiac death or MI; CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial
infarction; TLF ¼ target lesion failure; TLR ¼ target lesion revascularization.Conclusions: In patients treated with 1-stent technique for non-left main coronary
bifurcation lesions, residual SB DS 50% may be associated with a worse clinical
outcome compared to residual SB DS < 50%. These ﬁndings need to be conﬁrmed in
randomized controlled trials.
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Background: To evaluate the clinical and angiographic outcome of mini-crush
stenting for the treatment of true coronary bifurcation lesions. Percutaneous treatment
of coronary bifurcations lesions (CBL) is associated with a low procedural success rate
and high incidence of target lesion revascularization (TLR), and stent thrombosis. The
provisional approach is accepted as the default technique, but stent implantation on
both branches of the bifurcations is still required in 15%-30% of cases. The “mini-
crush” is one of the techniques used to implant stents on both branches of a CBL and
provides complete coverage of the ostium of the side branch, while minimizing the
length of the crushed stent. Data about outcomes for this technique are limited.
Methods: Between January 2006 and December 2012, 98 consecutive patients un-
derwent implantation of DES with mini-crush technique for the treatment of true CBL.
Clinical follow-up at our out-patient clinic was performed at 1-year. For the ﬁrst 50
patients an angiographic control was scheduled at 9 months.
Results: Clinical presentation was an acute coronary syndrome (ACS) in 71% of the
cases and stable coronary artery disease in the remaining 29%. Unprotected left main
was treated in 27% of patients. Two-step kissing balloon inﬂation and ﬁnal kissing
balloon inﬂation was systematically performed. First-generation DES were used in
90% of patients. Immediate procedural success was obtained in all of the cases. One
episode of deﬁnite stent thrombosis was documented 10 days after the index proce-
dure (premature DAP discontinuation). No deaths were documented. The 1-year cu-
mulative incidence of MACE was 5%: 2 episodes of myocardial infarction, and 3JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Corepeat procedure of revascularization. Angiographic restenosis was documented in 8%
(4/50 patients) and was localized at the ostium of the side branch in all of the cases.
Conclusions: Our results suggest that the treatment of bifurcation lesions by means of
mini-crush stenting technique is associated with excellent immediate success and
provides good angiographic and clinical outcomes at 1-year in a high-risk patients
population.
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Background: The strut thickness and deliverability of bioresorbable vascular scaffold
(BVS) may lead to more challenging for bifurcation lesions. Furthermore, all data
concerning BVS feasibility for bifurcation lesions are still limited.
Methods: We analyzed clinical outcome data of patients treated with BVS between
May 2012 and May 2014. The measured end-points were cardiac death, follow-up
myocardial infarction (MI), target lesion revascularization (TLR), target-vessel
revascularization (TVR) and major adverse cardiac events (MACE) deﬁned as com-
bination of cardiac death, follow-up MI and TVR.
Results: A total of 100 consecutive bifurcation lesions were successfully treated in 85
patients. The mean age was 62.8  11.6 years, and 88.6 % were males. Of these
lesions, 69 lesions were bifurcation lesions involving left anterior descending artery
(LAD) / diagonal branch and 5 lesions involved left main bifurcation lesions. True
bifurcation lesions (Medina classiﬁcation [1,1,1], [1,0,1], [0,0,1]) were observed in 64
lesions. Provisional single-stenting technique was used in 76 bifurcation lesions,
systematic double stenting technique was applied in 18 bifurcations with double BVS
in 13 lesions and mixed BVS-DES in 5 lesions (T-stenting in 11 lesions; Mini-crush
technique in 6 lesions; V-stenting technique in one lesion). Meticulous lesion prep-
aration with dedicated devices was needed in 19 lesions. Angiographic success was
achieved in 99.0%. At median follow-up of 231 days after the procedure, the overall
rates of cardiac death, MI, TLR, TVR and MACE were 0%, 1.2%, 5.9%, 7.1% and
8.2%, respectively. Deﬁnite stent thrombosis occurred in one case after discontinua-
tion of dual antiplatelet therapy.
Conclusions: Our results suggest that the treatment with BVS is feasible and effective
in a real life setting of bifurcation lesions, despite thick strut (> 150 mm) scaffolds and
limitation of side-branch access. Improvements in scaffold design may reduce the
need for meticulous lesion predilatation with dedicated devices and increase the
spectrum of lesions amenable to treatment with BVS.
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Background: PCI of bifurcation lesions is associated with higher rates of restenosis
and stent thrombosis compared to non-bifurcation lesions. In the e-BioMatrix registry
we compared the 2 year outcomes of bifurcation and non-bifurcation lesions treated
with one or more BioMatrix or BioMatrix Flex drug-eluting stents (BES). These
stents have an abluminal biodegradable polymer coating that releases Biolimus A9.
The coating fully absorbs within 6-9 months of implantation.
Methods: A total of 504 patients had PCI of at least one bifurcation lesion, 4968
patients were in the non-bifurcation subgroup. The primary endpoint was Major
Adverse Cardiovascular Events (MACE) deﬁned as a composite of cardiac death,
myocardial infarction (MI) and clinically-indicated target vessel revascularization (ci-
TVR) at 12 months. Secondary endpoints were MACE at 30 days, 6 months, 2 and 3
years, stent thrombosis (ST), major bleeding (MB) and total revascularization rates at
30 days, 6 months, 12 months, 2 and 3 years. Dual anti-platelet therapy (DAPT)
treatment was mandatory for 6 months and recommended up to 12 months.
Results: Clinical follow-up at 2 years was obtained in 95.2% of the bifurcation
subgroup and 93.7% of the non-bifurcation subgroup. DAPT compliance at 2 years
was of 30.9% vs. 30.5% respectively (p¼NS). A single stent strategy was employed in
79.9% of patients. MACE rates at 2 years were 10.9% vs. 6.4% (p< 0.001) in the
bifurcation and non-bifurcation groups, respectively. This difference was driven
principally by MI (4.7% vs. 2.2%, p< 0.001) and ci-TVR (8.1% vs. 3.9%, p< 0.001)
with no difference in cardiac death (1.2% vs. 1.5%, p¼0.6). Both peri-procedural
(1.6% vs. 0.4%, p¼0.002) and spontaneous MIs (2.3% vs. 1.1%, p¼0.02) wereronary Lesions - Bifurcations B55
